A Prospective,Open-label, Dose Escalation Phase 1 Study to Investigate the Safety, and Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of a HLX07, in Patients With Advanced Solid Cancers.
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2018
At a glance
- Drugs HLX 07 (Primary) ; Dexamethasone; Diphenhydramine; Ondansetron; Paracetamol
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Henlius Biotech
- 11 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 11 Mar 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2018.
- 24 Jan 2017 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.